The DOI matches its Crossref record; 223 of the 223 references it cites were found in a registry or an index.
Cancer and liver cirrhosis: implications on prognosis and management
Open accessAbstract
Liver cirrhosis, the end-stage of every chronic liver disease, is not only the major risk factor for the development of hepatocellular carcinoma but also a limiting factor for anticancer therapy of liver and non-hepatic malignancies. Liver cirrhosis may limit surgical and interventional approaches to cancer treatment, influence pharmacokinetics of anticancer drugs, increase side effects of chemotherapy, render patients susceptible for hepatotoxicity, and ultimately result in a competitive risk for morbidity and mortality. In this review, we provide a concise overview about the impact of liver cirrhosis on the management and prognosis of patients with primary liver cancer or non-hepatic malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–223 of 223
Roy, V., Pockaj, B., Northfelt, D., Allred, J., Liu, H., Nikcevich, D. A., Mattar, B. I., & Perez, E. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.563 · Cited by 61
Sohn, W., Paik, Y., Cho, J., Lim, H. Y., Ahn, J. M., Sinn, D. H., Gwak, G., Choi, M. S., Lee, J. H., Koh, K. C., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.009 · Cited by 59
Eckel, F., von Delius, S., Mayr, M. F., Dobritz, M., Fend, F., Hosius, C., Schleyer, E., Schulte‐Frohlinde, E., Schmid, R. M., & Lersch, C. (2005) · Oncology · doi:10.1159/000089990 · Cited by 56
Montomoli, J., Erichsen, R., Christiansen, C. F., Ulrichsen, S. P., Pedersen, L. H., Nilsson, T., & Sørensen, H. T. (2013) · BMC Gastroenterology · doi:10.1186/1471-230x-13-66 · Cited by 55
Surgery in the Patient with Liver Disease
Muilenburg, D. J., Singh, A., Torzilli, G., & Khatri, V. P. (2009) · Anesthesiology Clinics · doi:10.1016/j.anclin.2009.09.007 · Cited by 48
Portal Vein Thrombosis in Cirrhosis
Raja, K., Jacob, M. O., & Asthana, S. (2014) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2013.12.003 · Cited by 46
Minami, H., Kawada, K., Sasaki, Y., et al. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.00992.x · Cited by 44
Kubo, S., Takemura, S., Sakata, C., Urata, Y., & Uenishi, T. (2013) · Liver Cancer · doi:10.1159/000346214 · Cited by 43
D'Amico, M., Mejías, M., García‐Pras, E., Abraldeṣ, J. G., García‐Pagán, J. C., Fernández, M., & Bosch, J. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00252.2011 · Cited by 39
Jang, H. J., Kim, J. H., Song, H. H., Woo, K. H., Kim, M. S., Kae, S. H., Lee, J., Cho, J. W., Kang, J. H., Lee, S. I., et al. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-007-9884-3 · Cited by 38
Schaaf, L. J., Hammond, L. A., Tipping, S. J., Goldberg, R. M., Goel, R., Kuhn, J. G., Miller, L. L., Compton, L. D., Cisar, L. A., Elfring, G. L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2152 · Cited by 37
Impact of the MELD allocation after its implementation in liver transplantation
Benckert, C., Quante, M., Thelen, A., Bartels, M. J., Laudi, S., Berg, T., Kaisers, U. X., & Jonas, S. (2011) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2011.568521 · Cited by 35
Yang, Y., Liu, R., Lee, P., Yeh, Y., Huang, Y., Lee, W., Lee, K., Hsieh, Y., Lee, F., Tan, T., et al. (2013) · Liver International · doi:10.1111/liv.12299 · Cited by 34
The combination of olaparib and camptothecin for effective radiosensitization
Miura, K., Sakata, K.-I., Someya, M., Matsumoto, Y., Matsumoto, H., Takahashi, A., & Hareyama, M. (2012) · Radiation Oncology · doi:10.1186/1748-717x-7-62 · Cited by 33
Incidence and mortality trends for biliary tract cancers in Austria
Pinter, M., Hucke, F., Zielonke, N., Waldhoer, T., Trauner, M. A., Peck‐Radosavljevic, M., & Sieghart, W. (2013) · Liver International · doi:10.1111/liv.12325 · Cited by 32
Self-citationChallenges in managing hepatitis C virus infection in cancer patients
Borchardt, R. A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i11.2771 · Cited by 32
Cancer Chemotherapy I: Hepatocellular Injury
Rodriguez-Frias, E. A., & Lee, W. M. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.06.007 · Cited by 29
Should cirrhosis change our attitude towards treating non‐hepatic cancer?
Cabibbo, G., Palmeri, L., PALMERI, S., & Craxì, A. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02629.x · Cited by 28
O’Bryant, C. L., Haluska, P., Rosen, L. S., Ramanathan, R. K., Venugopal, B., Leong, S., Boinpally, R., Franke, A., Witt, K., Evans, J., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1733-6 · Cited by 27
Jeong, O., Park, Y. K., Jung, M. R., & Ryu, S. Y. (2015) · Medicine · doi:10.1097/md.0000000000000259 · Cited by 26
1 Clinical evaluation of liver disease
Simpson, K. J., & Finlayson, N. D. C. (1995) · Baillière s Clinical Gastroenterology · doi:10.1016/0950-3528(95)90054-3 · Cited by 21
Refining Sorafenib Therapy: Lessons from Clinical Practice
Bolondi, L., Craxì, A., Trevisani, F., Daniele, B., Costanzo, G. G. D., FAGIUOLI, S., Cammà, C., Bruzzi, P., Danesi, R., Spandonaro, F., et al. (2014) · Future Oncology · doi:10.2217/fon.14.261 · Cited by 21
Lee, S. H., Song, I. H., Noh, R., Kang, H. Y., Kim, S. B., Ko, S. Y., Lee, E. S., Kim, S. H., Lee, B. S., Kim, A. N., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1273-2 · Cited by 20
Cited by
Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy
Pinter, M., & Jain, R. K. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5616 · Cited by 332
Self-citationScheiner, B., Pomej, K., Kirstein, M. M., Hucke, F., Finkelmeier, F., Waidmann, O., Himmelsbach, V., Schulze, K., von Felden, J., Fründt, T. W., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.035 · Cited by 303
Self-citationMa, X., Yu, C., Wang, P., Xu, W., Wan, X., Lai, C. S. E., Liu, J., Koroleva-Maharajh, A., & Chen, S. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.09.026 · Cited by 281
Álvarez-Mercado, A. I., Caballeria-Casals, A., Rojano-Alfonso, C., Chávez-Reyes, J., Micó-Carnero, M., Sanchez-Gonzalez, A., Casillas-Ramírez, A., Gracia-Sancho, J., & Peralta, C. (2021) · Biomedicines · doi:10.3390/biomedicines9091158 · Cited by 12
Ullah, I., Seo, K., Wi, H., Kim, Y., Lee, S., & Ock, S. A. (2020) · Animal Cells and Systems · doi:10.1080/19768354.2020.1823473 · Cited by 4
“However, this strategy is not viable for many patients with liver disorders owing the limited supply of organs (Pinter et al. 2016; Artur et al. 2017).”
Background
Metadata
- Authors
- Pinter, M., Trauner, M., Peck-Radosavljevic, M., & Sieghart, W.
- Venue
- ESMO Open
- Publisher
- Elsevier BV
- Published
- 2016
- Volume
- 1
- Issue
- 2
- Pages
- e000042
- ISSN
- 2059-7029 (ISSN-L)
- OpenAlex
- W2318933482
- Cited by
- 295
- References
- 223
- FWCI
- 15.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.